期刊名称：JOURNAL FOR IMMUNOTHERAPY OF CANCER ISSN： 2051-1426 出版频率： Continuous publication 出版社： BMJ PUBLISHING GROUP, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND, WC1H 9JR   出版社网址： https://www.biomedcentral.com/ 期刊网址： https://jitc.biomedcentral.com/ 影响因子： 13.751 主题范畴： ONCOLOGY;    IMMUNOLOGY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and scope Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. JITC publishes high quality original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal. Together, these articles make JITC the leading forum for research in tumor immunology and cancer immunotherapy. Read more, explore our article types and sections, and submit your manuscript. Open access All articles published by Journal for ImmunoTherapy of Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here. As authors of articles published in Journal for ImmunoTherapy of Cancer you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement. For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed. Article-processing charges Open access publishing is not without costs. Journal for ImmunoTherapy of Cancer therefore levies an article-processing charge of £1540.00/$2410.00/€1965.00 for each article accepted for publication, plus VAT or local taxes where applicable. If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page. BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service. Indexing services Articles published in Journal for ImmunoTherapy of Cancer are included in: Directory of Open Access Journals (DOAJ) MEDLINE PubMed PubMed Central Science Citation Index Expanded (SCIE) Scopus The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink. Peer-review policy Peer review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help Editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here. Journal for ImmunoTherapy of Cancer operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript. Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board. The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks. Authors will be able to check the progress of their manuscript at any time by logging into the journal's submission system Editorial Manager. Editorial policies All manuscripts submitted to Journal for ImmunoTherapy of Cancer should adhere to BioMed Central's editorial policies. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Citing articles in Journal for ImmunoTherapy of Cancer Articles in Journal for ImmunoTherapy of Cancer  should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number. Article citations follow this format: Authors: Title. Journal for ImmunoTherapy of Cancer [year], [volume number]:[article number]. e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Journal for ImmunoTherapy of Cancer 2009, 1:115. refers to article 115 from Volume 1 of the journal. Appeals and complaints If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher. Instructions to Authors Submission guidelines How to determine your article type Article Type Recommendations  Case reports •    250-350-word structured abstract  •    1,500-2,500 words main text •    1-4 tables and/or figures •    25 references Clinical trials monitor •    250-350-word abstract •    4,000-5,000 words main text •    1-2 figures and/or tables •    50-75 references on average Commentary •    100-200-word abstract •    1,000-1,500 words main text •    Up to 1 figure and/or table •    Up to 10 references Hypothesis •    100-200-word abstract •    500-1500 words main text •    Up to 2 figure and/or table •    Up to 10 references Meeting report •    250-350-word abstract •    2,000-4,000 words main text •    1-4 figures and/or tables •    10-30 references Position article and guidelines •    250-350-word abstract  •    4,000-5,000 words main text •    1-4 figures and/or tables •    30-50 references Research article •    250-350-word structured abstract •    4,000-5,000 words main text •    5-7 tables and/or figures (Please keep the number of panels per figure to a minimum) •    50 references Review •    250-350-word abstract •    4,000-5,000 words main text •    1-4 figures and/or tables (Please keep the number of panels per figure to a minimum) •    50-100 references Short Report •    250-350-word abstract  •    1,500-2,500 words main text •    1-4 tables and/or figures •    25 references Our 3-step submission process   Before you submit Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit. Make sure you are submitting to the most suitable journal -Aims and scope Understand the costs and funding options -Fees and funding Make sure your manuscript is accurate and readable -Language editing services Understand the copyright agreement -Copyright   Ready to submit To give your manuscript the best chance of publication, follow these policies and formatting guidelines. Journal for ImmunoTherapy of Cancer publishes the following article types: Case report Clinical trials monitor Commentary Hypothesis Meeting report Position article and guidelines Research article Review Short report Click the relevant link to find style and formatting information for the article you are going to submit. General formatting rules for all article types -Preparing your manuscript Make sure your submission is complete -Prepare supporting information Copyright and license agreement -Conditions of publication Read and agree to our Editorial Policies -Editorial policies   Submit and promote After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond. Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.  Who decides whether my work will be accepted? -Peer-review policy Want to submit to a different journal? -Manuscript transfers Spreading the word -Promoting your publication Submit your manuscript in Editorial Manager Editorial Board Editor-in-Chief  Prof Pedro Romero, Ludwig Center for Cancer Research, Switzerland Section Editors Basic tumor immunology Prof Cornelis JM Melief, ISA Therapeutics BV, Netherlands  Case reports  Prof Alfred Zippelius, University Hospital Basel, Switzerland Clinical trials monitor  Dr Leisha A Emens, Johns Hopkins University, USA Clinical/translational cancer immunotherapy  Dr James L Gulley, National Cancer Institute, National Institutes of Health, USA Commentary/editorials  Dr Christian Capitini, University of Wisconsin Madison, USA Guidelines and Consensus Statements  Dr Robert L Ferris, University of Pittsburgh, USA Immunotherapy biomarkers  Dr Lisa H Butterfield, University of Pittsburgh, USA Reviews  Dr Sandra Demaria, Weill Cornell Medical College, USA Prof Thomas F Gajewski, University of Chicago, USA Associate Editors Basic tumor immunology Dr Scott I Abrams, Roswell Park Cancer Institute, USA Prof Paul A Antony, University of Maryland, USA Dr Timothy NJ Bullock, University of Virginia, USA Prof Gennaro Ciliberto, IRCCS Istituto Nazionale Tumori, Italy  Prof Michael A Curran, MD Anderson Cancer Center, USA Dr Jonathan L. Curry, MD Anderson Cancer Center, USA Dr Madhav V Dhodapkar, Yale University, USA Dr Norman M Greenberg, Atreca, USA Dr Arthur A Hurwitz, Agenus, USA Dr Masahisa Jinushi, Merck & Co., Inc., Japan  Prof Khashayarsha Khazaie, Northwestern University, USA Dr Christopher A Klebanoff, Memorial Sloan Kettering Cancer Center, USA Dr Michelle Krogsgaard, New York University, USA Dr David H Munn, Augusta University, USA Dr Pamela S Ohashi, Ontario Cancer Institute, Canada  Dr Maria Rescigno, European Institute of Oncology, Italy  Dr Sjoerd H Van der Burg, Leiden University Medical Center, Netherlands  Dr Andrew D Weinberg, Earle A. Chiles Research Institute, USA Case reports Dr Djordje Atanackovic, University of Utah, USA Dr Jack Bui, University of California San Diego, USA Dr Richard D. Carvajal, Columbia University Medical Center, USA Dr Heinz Laubli, University Hospital Basel, Switzerland Prof Sebastian Kobold, Ludwig Maximilians University of Munich, Germany Prof Andreas Mackensen, University Hospital Erlangen, Germany Dr Olivier Michielin, University of Lausanne, Switzerland Dr Hiroyoshi Nishikawa, National Cancer Center, Japan Dr Max Topp, University of Würzburg, Germany Dr Michael von Bergwelt-Baildon, University of Cologne, Germany Dr Geoffrey R. Weiss, University of Virginia, USA Dr Hassane Zarour, University of Pittsburgh, USA Clinical trials monitor Dr Stephen Ansell, Mayo Clinic, USA Dr Jonathan Cebon, Ludwig Institute for Cancer Research, Australia Dr Tai-Tsang Chen, Columbia University; BMS, USA Dr Jolanda de Vries, Radboud University Nijmegen, Netherlands Dr Silvia Formenti, Weill Cornell Medical College, USA Dr Howard Kaufman, Rutgers Cancer Institute of New Jersey, USA Dr Larry Kwak, City of Hope, USA Dr Sherene Loi, Peter MacCallum Cancer Centre, Australia Dr Kunle Odunsi, Roswell Park Cancer Institute, USA Dr Michael Postow, Memorial Sloan-Kettering Cancer Center, USA Prof Peter Schmid, Imperial College London, United Kingdom Dr Hiroshi Shiku, Mie University Graduate School of Medicine, Japan Dr Daniel Speiser, Ludwig Institute for Cancer Research, Switzerland Dr Louis Weiner, Georgetown University Lombardi Cancer Center, USA Dr Yi-Long Wu, Guangdong General Hospital and Academy of Medical Sciences, China Dr Xiabo Ye, Johns Hopkins University School of Medicine, USA Clinical/translational cancer immunotherapy Dr Paolo A Ascierto, Istituto Nazionale Tumori Fondazione G. Pascale, Italy  Dr Ernest C Borden, The Cleveland Clinic Foundation, USA Dr Charles Drake, Columbia University Medical Center, USA Dr Robert L Ferris, University of Pittsburgh Cancer Institute, USA Dr Lawrence Fong, University of California, San Francisco, USA Dr Nancy M Hardy, University of Maryland, USA Dr Kristen Hege, Celgene Corp, USA Dr Christian S Hinrichs, National Cancer Institute, ETIB, USA Dr Pawel Kalinski, Roswell Park Comprehensive Cancer Institute, USA Dr Yutaka Kawakami, Keio University School of Medicine, Japan  Dr Samir N Khleif, Augusta University, USA Dr Beatrix Kotlan, National Institute of Oncology, Hungary  Dr Ada M Kruisbeek, DCPrime, The Netherlands  Dr Dung Le, Johns Hopkins University, USA Prof Alessandro Lugli, University of Bern, Switzerland  Dr Michele Maio, University Hospital of Siena, Italy  Dr Ravi A Madan, National Cancer Institute, National Institutes of Health, USA Prof Ignacio Melero, Univerity of Navarra, Spain  Prof Giorgio Parmiani, Fondazione C.S. Raffaele Del Monte Tabor, Italy  Dr Anna C Pavlick, NYU Cancer Institute, USA Dr Padmanee Sharma, MD Anderson Cancer Center, USA Dr Jeffrey S Weber, NYU Langone Medical Center, USA Dr Cassian Yee, MD Anderson Cancer Center, USA Commentary/editorials Dr Ana Anderson, Harvard University, USA Prof Wolf-Hervé Fridman, Cordeliers Research Center, France  Prof Bryon D Johnson, Medical College of Wisconsin, USA Dr Douglas McNeel, University of Wisconsin, USA Dr William J Murphy, University of California, Davis, USA Dr Gabriel Rabinovich, Instituto de Biologia y Medicina Experimental, Argentina  Dr William L Redmond, Earle A. Chiles Research Institute, USA Prof Paul M Sondel, University of Wisconsin, USA Guidelines and consensus statements Prof Paulo A. Ascierto, Istituto Nazional Tumori-Fondazione 'G.Pascale', Italy Dr Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, USA Dr Michael R. Bishop, University of Chicago, USA Prof Michael Platten, Ruprecht-Karls University Heidelberg, Germany Immunotherapy biomarkers Dr Alessandra Cesano, Nanostring, Inc., USA Dr Michael Kalos, Janssen Oncology, USA Dr Thomas Kleen, Precision for Medicine, Germany  Dr Rejean Lapointe, Universite De Montreal, University Hospital (CRCHUM), Canada  Dr Laszlo Radvanyi, Ontario Institute for Cancer Research, Canada Dr Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori, Italy  Dr Kimberly A Shafer-Weaver, AstraZeneca, USA Dr Craig L Slingluff, University of Virginia, USA Dr Ena Wang, Abbvie, USA Dr Jianda Yuan, Merck & Co., USA Reviews Dr Michael B Atkins, Georgetown-Lombardi Comprehensive Care Center, USA Dr Ira Mellman, Genentech, USA Dr James J Mule, H. Lee Moffitt Comprehensive Cancer Center, USA